{"organizations": [], "uuid": "3bb2cdaa21b7462fe9ca44b516b78f61bf5c98df", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/10", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/10/globe-newswire-obalon-announces-first-quarter-2018-financial-results.html", "country": "US", "domain_rank": 767, "title": "Obalon Announces First Quarter 2018 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.415, "site_type": "news", "published": "2018-05-11T00:01:00.000+03:00", "replies_count": 0, "uuid": "3bb2cdaa21b7462fe9ca44b516b78f61bf5c98df"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/10/globe-newswire-obalon-announces-first-quarter-2018-financial-results.html", "ord_in_thread": 0, "title": "Obalon Announces First Quarter 2018 Financial Results", "locations": [], "entities": {"persons": [{"name": "todd wood", "sentiment": "none"}], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "obalon therapeutics, inc.", "sentiment": "neutral"}, {"name": "global sales the company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO, Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its unaudited financial results as of and for the first quarter ended March 31, 2018.\nFirst Quarter 2018 highlights:\nHighest number of treating accounts ever, up 40% vs Q4-17 and 300% vs Q1-17 Highest number of patients treated ever, up over 60% vs Q4-17 and 240% vs Q1-17 Highest unique website visits ever, up over 70% vs Q4-17 and over 260% vs Q1-17 Highest Find-A-Doctor searches ever, up 55% vs Q4-17 and over 600% vs Q1-17 Todd Wood joins as new Vice President of Global Sales\nThe Company reported revenue of $1.3 million for the first quarter of 2018, compared to $1.5 million for the first quarter of 2017. Net loss was reported at $12.1 million compared to a net loss of $7.7 million in the first quarter of 2017 and net loss per share for the quarter was $0.71 as compared to net loss per share of $0.47 in the first quarter of 2017.\nCost of revenue was $0.8 million during the three months ended March 31, 2018, in-line with $0.8 million for the prior year period. Gross profit for the first quarter of 2018 was $0.6 million, resulting in a gross margin of 43%, compared to a gross profit of $0.6 million and gross margin of 44% for the first quarter of 2017.\nResearch and Development expense for the first quarter of 2018 totaled $2.6 million, up from $2.4 million in the first quarter of 2017, and Selling, General and Administrative expense increased to $10.0 million for the first quarter of 2018, compared to $5.9 million in the first quarter 2017. Selling, General and Administrative expenses in the first quarter 2018 included approximately $1.3 million related to investigation of the whistleblower allegations and terminated equity offering.\nOperating loss for the first quarter of 2018 was $12.1 million, compared to an operating loss of $7.7 million for the first quarter of 2017.\nAs of March 31, 2018, cash and cash equivalents were $33.5 million and debt was $10.0 million.\n“In Q1-18, we continued the second half of our New Year’s Resolution Promotion strategy with an increased focus on driving utilization at the account level,” said Bill Plovanic, CFO. “Although first quarter revenues were slower than Q4-17, we were very pleased with the underlying metrics as we strive to build a sustainable business. New patient starts, the number of accounts treating, unique website visits and Find-A-Doctor searches grew meaningfully and were the highest level ever.”\nCall Information\nA conference call to discuss first quarter 2018 financial results is scheduled for today, May 10, 2018, at 5:00 PM Eastern Time (2:00 PM Pacific Time). Interested parties may access the conference call by dialing (844) 889-7791 (U.S.) or (661) 378-9934 (international) using passcode 3693617. Media and individuals will be in a listen-only mode. Participants are asked to dial in a few minutes prior to the call to register for the event. The conference call will also be webcast live at: https://edge.media-server.com/m6/p/q4jkh9dx.\nAn archive of the webcast will be available for twelve months following the event on the Obalon Therapeutics, Inc. website located at http://investor.obalon.com in the “News & Events” section.\nAbout Obalon Therapeutics, Inc.\nObalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com .\nFor Obalon Therapeutics, Inc.\nInvestor Contact:\nWilliam Plovanic\nChief Financial Officer\nObalon Therapeutics, Inc.\nOffice: +1 760 607 5103\nwplovanic@obalon.com\nMedia:\nMegan Driscoll\nEvolveMKD\nOffice Phone: +1 646 517 4220\nmdriscoll@evolvemkd.com\nOBALON THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except shares and per share data) Three Months Ended March 31, 2018 2017 (Unaudited) Revenue $ 1,346 $ 1,472 Cost of revenue 769 823 Gross profit 577 649 Operating expenses: Research and development 2,639 2,400 Selling, general and administrative 10,006 5,940 Total operating expenses 12,645 8,340 Loss from operations (12,068 ) (7,691 ) Interest expense, net (37 ) (54 ) Other expense (21 ) — Net loss (12,126 ) (7,745 ) Other comprehensive income (loss) 6 (18 ) Net loss and comprehensive loss $ (12,120 ) $ (7,763 ) Net loss per share, basic and diluted $ (0.71 ) $ (0.47 ) Weighted-average common shares outstanding, basic and diluted 16,986,656 16,562,030\nOBALON THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except shares and par value data) March 31, 2018 December 31, 2017 Assets (Unaudited) Current assets: Cash and cash equivalents $ 33,478 $ 21,108 Short-term investments — 23,292 Accounts receivable, net of allowance of $621 and $239, respectively 2,553 4,223 Inventory 1,867 1,418 Other current assets 1,187 1,714 Total current assets 39,085 51,755 Property and equipment, net 1,422 1,346 Total assets $ 40,507 $ 53,101 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 2,304 $ 1,276 Accrued compensation 1,831 4,494 Deferred revenue 337 510 Other current liabilities 1,677 1,773 Current portion of long-term loan 2,961 1,958 Total current liabilities 9,110 10,011 Deferred rent — 13 Long-term loan, excluding current portion 6,973 7,964 Total long-term liabilities 6,973 7,977 Total liabilities 16,083 17,988 Commitments and contingencies Stockholders’ equity: Common stock, $0.001 par value; 300,000,000 shares authorized as of March 31, 2018 and December 31, 2017; 17,596,282 and 17,500,604 shares issued and outstanding as of March 31, 2018 and December 31, 2017, respectively 18 18 Additional paid-in capital 147,905 146,474 Accumulated other comprehensive gain (loss) 1 (5 ) Accumulated deficit (123,500 ) (111,374 ) Total stockholders’ equity 24,424 35,113 Total liabilities and stockholders’ equity $ 40,507 $ 53,101\nOBALON THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Three Months Ended March 31, 2018 2017 (Unaudited) Operating activities: Net loss $ (12,126 ) $ (7,745 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 129 66 Stock-based compensation 1,389 463 Loss on disposal of fixed assets 107 — (Accretion) amortization of investment (discount) premium, net (5 ) 3 Amortization of debt discount 11 10 Change in operating assets and liabilities: Accounts receivable, net 1,670 (1,035 ) Accounts receivable from related party — 515 Inventory (449 ) (101 ) Other current assets 527 240 Accounts payable 1,074 217 Accrued compensation (2,663 ) (942 ) Deferred revenue (173 ) 50 Other current and long term liabilities (93 ) (94 ) Net cash used in operating activities (10,602 ) (8,353 ) Investing activities: Purchases of short-term investments — (25,029 ) Maturities of short-term investments 23,302 2,500 Purchase of property and equipment (358 ) (381 ) Net cash provided by (used in) investing activities 22,944 (22,910 ) Financing activities: Proceeds from sale of common stock upon exercise of stock options 28 — Net cash provided by financing activities 28 — Net increase (decrease) in cash and cash equivalents 12,370 (31,263 ) Cash and cash equivalents at beginning of period 21,108 72,975 Cash and cash equivalents at end of period $ 33,478 $ 41,712 Supplemental cash flow information: Interest paid $ 149 $ 130 Property and equipment in accounts payable $ 46 $ 129\nSource:Obalon Therapeutics, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=_o3IFCQ10r98z_na4Mcmm8Mij7QOkJ9t1atHT1KQWWOWdZ2WCKvgdeyCAK5OArSU0Y71tpGH_Ho_65flPwyBwGORHoKkX0vZZQJojtMotTeWOpFs7XzNT993AwzFKA_Xj2LmlfaIjQB_m_jazl_2btYZelMrH_AqlQnrHnsEuJ5nO4CV4piOp6sH35PeYDJSPMcTxFo97n4VQqzMnStSykXtUJO6sVzBuZx6BxaUWY7Jx8VDoi3H6P3CBilkC049TFU7Z7A-iqSbO26AYFYTeg==", "https://www.globenewswire.com/Tracker?data=W5eT6YzBL0NF_eUB8ATM3RIRhTnzxmnYTrkPTEzMzbEaGOFNlQUWrBBSRga6n1KOmO-IVp7TAv1951MjEBnYTI8636aNxUUAuRKC1bCttgg=", "https://www.globenewswire.com/Tracker?data=on5pOq_Zxmzn5meYa3KUVuMX9VM3Xk9FZgc1pFMNQypYzCsBkhX5PECMuDnSaRY47QoO0KMCK1iOfSY5OFcMbxV1E3Vcwftvy4iWdshVWUk=", "https://edge.media-server.com/m6/p/q4jkh9dx.", "https://www.globenewswire.com/Tracker?data=D-g1epU6kdHn5Xv2c2jnF2CCHoaYCQRkQACZV-QMT0nrmoRkZztgCinRvdhtBG2MUK5zEOrfUND7iWZDu4KcgQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/e02ca260-1349-45d0-a97e-755cdb8403b4"], "published": "2018-05-11T00:01:00.000+03:00", "crawled": "2018-05-11T00:52:44.002+03:00", "highlightTitle": ""}